

AMENDMENTS TO THE CLAIMS

1. (Previously presented) An aqueous liquid preparation consisting essentially of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, and a water-soluble metal chloride in a light-stabilizing effective amount, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.

2. (Cancelled)

3. (Previously presented) The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from sodium chloride, potassium chloride and calcium chloride.

4. (Cancelled)

5. (Previously presented) The aqueous liquid preparation of claim 1, which is an acid addition salt of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid.

6. (Original) The aqueous liquid preparation of claim 5, wherein the acid addition salt is monobenzenesulfonate.

7. (Previously presented) The aqueous liquid preparation of claim 1, wherein the aqueous liquid preparation has a pH in the range of 4-8.5.

8. (Previously presented) The aqueous liquid preparation of claim 1, which is an eye drop.

9. (Previously presented) The aqueous liquid preparation of claim 1, which is a nasal drop.

10. (Currently amended) An aqueous eye drop ~~comprising~~consisting essentially of, in an aqueous solution, (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesulfonate, as the only active ingredient, and sodium chloride at not less than 0.2 w/v% and not more than 0.8 w/v% in a light-stabilizing effective amount.

11. (Cancelled)

12. (Previously presented) The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from alkali metal chlorides and alkaline earth metal chlorides.

13. (Previously presented) An aqueous eye drop consisting essentially of an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is light-stabilized with a water-soluble metal chloride, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.

14. (Previously presented) An aqueous liquid preparation consisting of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, a water-soluble metal chloride in a light-stabilizing effective amount, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%, benzalkonium chloride, sodium dihydrogenphosphate dihydrate, sodium hydroxide and water.